212 related articles for article (PubMed ID: 9674732)
21. Cell cycle-dependent fluctuation of urokinase-type plasminogen activator, its receptor, and inhibitors in cultured bovine mammary epithelial and myoepithelial cells.
Zavizion B; White JH; Bramley AJ
Biochim Biophys Acta; 1998 Jun; 1403(2):141-50. PubMed ID: 9630579
[TBL] [Abstract][Full Text] [Related]
22. Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
Sałuda-Gorgul A; Pytel J; Olborski B; Greger J
Z Naturforsch C J Biosci; 2002; 57(3-4):366-71. PubMed ID: 12064742
[TBL] [Abstract][Full Text] [Related]
23. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
24. Retinoic acid potentiates phorbol ester-mediated induction of urokinase and plasminogen activator inhibitor type 2 in human myeloid leukemic cell lines.
Schuster WA; Medcalf RL; Kruithof EK
Endocrinology; 1993 Oct; 133(4):1724-30. PubMed ID: 8404615
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
26. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
27. Post-traumatic plasminogenesis in intraarticular exudate in the knee joint.
Rość D; Powierza W; Zastawna E; Drewniak W; Michalski A; Kotschy M
Med Sci Monit; 2002 May; 8(5):CR371-8. PubMed ID: 12011780
[TBL] [Abstract][Full Text] [Related]
28. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
[TBL] [Abstract][Full Text] [Related]
30. In vivo and in vitro expression of the plasminogen activators and urokinase type plasminogen activator receptor (u-PAR) in the pig oviduct.
Roldán-Olarte M; García DC; Jiménez-Díaz M; Valdecantos PA; Miceli DC
Anim Reprod Sci; 2012 Dec; 136(1-2):90-9. PubMed ID: 23103014
[TBL] [Abstract][Full Text] [Related]
31. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
32. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
33. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells.
Oszajca K; Bieniasz M; Brown G; Swiatkowska M; Bartkowiak J; Szemraj J
Biochem Cell Biol; 2008 Dec; 86(6):477-86. PubMed ID: 19088796
[TBL] [Abstract][Full Text] [Related]
34. Functional evaluation of plasmin formation in primary breast cancer.
Chappuis PO; Dieterich B; Sciretta V; Lohse C; Bonnefoi H; Remadi S; Sappino AP
J Clin Oncol; 2001 May; 19(10):2731-8. PubMed ID: 11352966
[TBL] [Abstract][Full Text] [Related]
35. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
36. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Kotani I; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Thromb Res; 1995 Mar; 77(6):493-504. PubMed ID: 7624837
[TBL] [Abstract][Full Text] [Related]
37. Expression profiles of fibrinolytic components in nasal mucosa.
Sejima T; Madoiwa S; Mimuro J; Sugo T; Ishida T; Ichimura K; Sakata Y
Histochem Cell Biol; 2004 Jul; 122(1):61-73. PubMed ID: 15197554
[TBL] [Abstract][Full Text] [Related]
38. Do fibrinolytic proteins of human bile derive exclusively from gall bladder?
Gil D; Michalski A; Kondera-Anasz Z; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2001 May; 7 Suppl 1():262-3. PubMed ID: 12211732
[TBL] [Abstract][Full Text] [Related]
39. Fibrin-specific fibrinolysis.
Collen D; Lijnen HR
Ann N Y Acad Sci; 1992 Dec; 667():259-71. PubMed ID: 1285022
[No Abstract] [Full Text] [Related]
40. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
